JAMA Finds Dozens of Websites Selling Unapproved Retatrutide and Zenagamtide, With Lab Tests Showing Wrong Doses and a Vial That Held Semaglutide
A JAMA Medical News report published October 9, 2026 found dozens of websites, promoted by TikTok and Instagram influencers, selling Eli Lilly's investigational triple agonist retatrutide and Novo Nordisk's GLP-1 and amylin drug zenagamtide, often labeled "for research purposes only" while giving dosing instructions. Neither drug is approved anywhere. Australia's drug regulator found a product labeled retatrutide that contained a high dose of semaglutide instead, and University of Queensland tests of three 10 mg vials found doses from about half to about twice the label; the FDA has sent 21 warning letters to retatrutide sellers since December 2024, according to the report.